Entity

Time filter

Source Type


Yanli X.,The First Municipal Peoples Hospital of Guangzhou | Shunqing W.,The First Municipal Peoples Hospital of Guangzhou | Qinghua D.,The First Municipal Peoples Hospital of Guangzhou | Jianjin X.,The First Municipal Peoples Hospital of Guangzhou
Journal of Leukemia and Lymphoma | Year: 2015

Objective To discriminate morphology and immunophenotype differences between hematogones and lymphoblast to provide some references for the correct identification of hematogones and minimal residual leukemia cells. Methods Immunophenotypes were detected by flow cytometry in a total of 132 bone marrow from 58 patients with acute B lymphoblastic leukemia during diagnosis, remission and relapse. Hematogones were identified based on combination of CD34/CD10/CD19/CD45 or CD34/CD10/CD45/CD19/CD20/CD38. Results Among 132 specimens, 45 (34 N) were identified hematogones, the detection range was 0-36 N. Three specimens appeared in diagnosis patients, one in relapse, and the remaining 41 cases in remission. The detection rate of hematogones was 62 N (41/66) in the remission cases. More than 5 N leukemia cells of nucleated cells were detected in diagnosis and relapse, and less than 5 N residual leukemia cells was in 24 specimens from remission patients. In 28 specimens, the co-existence of hematogones and leukemia cells was found, including three in diagnosis, one in relapse and the remaining 24 in remission. Hematogones were characterized in term of variable expression of CD45 and very low side scatter. The early hematogones expressed CD34. With maturation increasing, hematogones gradually lacked CD34. CD19 and CD10 were presented in whole hematogones stage. Early hematogones had expression of CD10. Lymphoblasts showed maturation arrest and more homogeneous populations. SSC values of hematogones were higher than that of normal B cell progenitors. Antigen overexpression or underexpression was not found in normal hematopoietic progenitor B cells, and hematopoietic progenitor B cells did not appear cross-lineage markers, CD20+ cells exhibited continuous distribution from negative to weak positive for normal hematogones. Conclusions Hematogones were present in diagnosis, remission and relapse cases with acute B lymphoblastic leukemia, especially abundant in bone marrow after chemotherapy. It should be careful to diagnose and discriminate the malignant cells from benign cells. By comprehending continuous and complete maturation spectrum of antigen expression for normal hematogones, knowing phenotype of leukemia cells drift change patterns and using multiparameter flow cytometry and optimal antibody combination, it is significant in identifying residual lymphoblasts from hematogones and improving the detection accuracy in minimal residual disease. © 2015 Editorial Board of Journal of Leukemia and Lymphoma. All rights reserved. Source


Mo L.,The First Municipal Peoples Hospital of Guangzhou | Jiang X.-Q.,The First Municipal Peoples Hospital of Guangzhou | Huang Y.-H.,The First Municipal Peoples Hospital of Guangzhou | Chen J.,The First Municipal Peoples Hospital of Guangzhou | Xu J.,The First Municipal Peoples Hospital of Guangzhou
Chinese Journal of Radiology | Year: 2011

Objective: To investigate the differential diagnostic features of subtypes of renal cell carcinoma(RCC) using dynamic contrast-enhanced MRI (DCE-MRI). Methods: The MRI appearances of 77 RCCs, including 55 clear cell RCCs(CCRCC), 14 papillary RCCs(PRCC) and 8 chromophobe RCCs (CRCC), were retrospectively analyzed and compared with findings of pathology. DCE-MRI was conducted in each case after intravenous administration of contrast agent. Region of interest measurements (cortical, nephrographic and delayed Phases) of signals within tumor and uninvolved renal cortex were used to calculate percentage signal intensity change and tumor-to-cortex enhancement index, and the data was analyzed by AVONA and t test. Results: On unenhanced and enhanced MRI, most CRCCs showed homogeneous signal (7/8). CCRCC and PRCC often show inhomogenous signal with necrosis (36/55, 7/14). Hemorrhage and cystic degeneration were often found in PRCC (9/14). On the cortical, nephrographic and delayed phase images, CCRCCs showed greater signal intensity change [(296.15 ± 60.27)%, (236.33 ± 58.31)% and (216.83 ± 46.72)%. respectively than PRCCs (79.70 ± 18.84)%, (122.81 ± 27.35)% and (117.55 ± 20.63)%, respectively], and CRCCs showed intermediate change [(119.56 ± 40.76)%, (163.06 ± 33.91)% and (179.72 ± 32.89)%, respectively]. A phenomenon of quick staining and quick fainting was observed in CCRCCs. Both of CRCCs and PRCCs showed delayed enhancement. The tumor-to-cortex enhancement index at the cortical, nephrography and delayed phases was highest for CCRCCs (1.26 ± 0.34, 0.92 ± 0.23 and 0.76 ± 0.14, respectively), lowest for PRCCs (0.33 ± 0.12, 0.41 ± 0.23 and 0.35 ± 0.11, respectively), and intermediate for CRCCs (0.54 ± 0.10, 0.62 ± 0.15 and 0.69 ± 0.12, respectively, P < 0.01). The degree of enhancement was significantly different among the 3 subtypes at the every contrast enhanced phase (F = 940.931, 124.515 and 38.194, P < 0.01), so was the tumor-to-cortex enhancement index (F = 798.625, 78.308 and 73.699, P < 0.01). There was a good consistency between MR appearances of the 3 RCC subtypes and pathological characteristics. Conclusion: DCE-MRI could distinctly show imaging features of CCRCC, PRCC and CRCC, which were related to their pathological characteristics, and these features were helpful in predicting a specific subtype of RCC. © 2011 by the Chinese Medical Association. Source


Gu J.-H.,The First Municipal Peoples Hospital of Guangzhou | Huang Y.-H.,The First Municipal Peoples Hospital of Guangzhou | Jiang X.-Q.,The First Municipal Peoples Hospital of Guangzhou | Ding H.-J.,The First Municipal Peoples Hospital of Guangzhou | And 2 more authors.
Chinese Journal of Medical Imaging Technology | Year: 2011

Objective: To observe the feasibility of DWI in evaluating cancer cell repopulation for rabbit models of hepatic VX2 tumor after radiotherapy. Methods: VX2 liver cancer models were established in 32 rabbits using celiac tumor block planting method. Three-dimensional stereotactic conformal radiation therapy was performed in each rabbit when the diameter of tumor is equal or greater than 1 cm (single radiation, dose 15 Gy). After radiotherapy, 32 rabbits were randomly averagely divided into four groups, and MRI was performed on 1st, 5th, 10th, 15th day, respectively with EPI-SE sequence and SENSE technology. DWI was performed with different b values (300, 500 and 600 s/mm 2). ROIs of VX2 tumor and normal liver tissue were selected, the ADC values of ROI as well as ADC tumor/ADC liver ratios were calculated, statistically analyzed and compared with pathology findings. Results: Signal intensity of VX2 tumor on DWI was higher than that of liver tissue. After radiotherapy, signal intensity of VX2 tumor became heterogeneous on T2WI. The signal of solid part decreased unevenly, while the necrotic cystic part showed very low signal on DWI, while ADC images behaved in the opposite way. Significant differences were found in ADC value and ADC tumor/ADC liver among different time groups with different b value. There were significant differences in ADC value and ADC tumor/ADC liver between every two groups. ADC tumor value and ADC tumor/ADC liver on the 5th day after operation were higher than that on 1st day, on the 10th day after operation were lower than that on the 5th day, on the 15th day after operation were lower than those on the 10th day. Changes of ADC values and ADC tumor/ADC liver accorded with cellular changes in pathological samples. Conclusion: Micro changes of tumor tissue can be reflected with DWI images through changes of ADC tumor images, ADC tumor values and ADC tumor/ADC liver. DWI can be used to monitor cancer cell repopulation of rabbit VX2 liver cancer at different time after radiotherapy. Source


Yan C.,Southern Medical University | Wu Y.,Southern Medical University | Feng J.,Southern Medical University | Chen W.,Southern Medical University | And 7 more authors.
International Journal of Nanomedicine | Year: 2013

Purpose: Pretargeting of biomarkers with nanoparticles in molecular imaging is promising to improve diagnostic specificity and realize signal amplification, but data regarding its targeting potential in magnetic resonance (MR) imaging are limited. The purpose of this study was to evaluate the tumor angiogenesis targeting efficacy of the anti-αvβ3 antibody guided three-step pretargeting approach with magnetoliposomes. Methods: Polyethylene glycol-modified and superparamagnetic iron oxide-encapsulated magnetoliposomes with and without biotin were synthesized and characterized. The cytotoxicity of both probes was evaluated using the methyl thiazdyl tetrazolium assay, and their cellular uptake by mouse macrophage was visualized using Prussian blue staining. Three-step pretargeting MR imaging was performed on MDA-MB-435S breast cancer-bearing mice by intravenous administration of biotinylated anti-αvβ3monoclonal antibodies (first step), followed by avidin and streptavidin (second step), and by biotinylated magnetoliposomes or magnetoliposomes in the targeted or nontargeted group, respectively (third step). The specificity of αvβ3 targeting was assessed by histologic examinations. Results: The developed magnetoliposomes were superparamagnetic and biocompatible as confirmed by cell toxicity assay. The liposomal bilayer and polyethylene glycol modification protected Fe3O4 cores from uptake by macrophage cells. MR imaging by three-step pretargeting resulted in a greater signal enhancement along the tumor periphery, occupying 7.0% of the tumor area, compared with 2.0% enhancement of the nontargeted group (P < 0.05). Histologic analysis demonstrated the targeted magnetoliposomes colocalized with neovasculature, which was responsible for the MR signal decrease. Conclusion: These results indicate that our strategy for MR imaging of αvβ3-integrin is an effective means for sensitive detection of tumor angiogenesis, and may provide a targetable nanodelivery system for anticancer drugs. © 2013 Yan et al, publisher and licensee Dove Medical Press Ltd. Source

Discover hidden collaborations